Hepatitis B Cure 2022
hepatitis b cure 2022 | Hepatitis B virus is one of the most prevalent serious liver diseases. The question is whether hepatitis B patient will be cured. What is new in the treatment of hepatitis B virus? Hepatitis B treatment depends on strengthening the bodys immunity and regulating liver enzymes, which helps in strengthening the body to overcome the B virus. That is why we will present to you today The b virus treatment that achieves this.
I was cured of hepatitis B after using this treatment for 9 months, so says one of the hepatitis B virus patients after using the KA HEPA treatment, which is manufactured by the Turkish company Kashgarli Sultan under the supervision of Dr. Marhoba Kashgarli Sultan, who confirmed the ability of the treatment to expel the hepatitis B virus. of blood completely.
Symptoms of hepatitis B:
Before learning about the new treatment for hepatitis B virus 2021-2022, let us know the symptoms of hepatitis B:
- The body of the patient with hepatitis C suffers from severe weaknesses.
- It also cuts off from food because of the interruption of appetite for eating.
- Hepatitis B has complications that lead to various liver diseases.
- Constant feeling of pain in the joints, muscles and abdomen.
- The patients temperature is also higher than normal.
- In addition, the patients urine color changes from normal to gray.
- Hepatitis B carrier also suffers from various digestive problems.
- The complications of hepatitis B virus also lead to jaundice and kidney failure.
The Life Cycle Of The Virus
The HBV life cycle begins following virion attachment to its receptor on the hepatocyte surface, now identified as the sodium taurocholate cotransporting polypeptide , which is a bile salt transporter . A stretch of amino acids in the pre-S1 domain is involved in virus binding . The interaction between the virus and its receptor can be prevented by neutralizing antibodies against HBsAg forming the basis for the prophylactic vaccination against HBV. Investigation of agents capable of blocking HBV entry and infection of new hepatocytes is currently in progress .
The steps of the hepatitis B virus life cycle, from viral entry into hepatocytes to release of mature virions into the extracellular space. The target sites of investigational antiviral agents are noted. NTCP, sodium taurocholate cotransporting polypeptide cccDNA, covalently closed circular DNA HBsAg, hepatitis B surface antigen HBeAg, hepatitis B e antigen.
Assembly of virus particles occurs in close association with the endoplasmic reticulum membrane. Mature nucleocapsids bud through the ER membrane into the lumen acquiring in the process their outer envelope containing the HBsAg proteins, already localized there. Ultimately virions are trafficked through the trans-Golgi to the hepatocyte surface via vesicular transport, from where they are released into the extracellular space .
Treatment For Acute Hepatitis B
If you’re diagnosed with hepatitis B, your GP will usually refer you to a specialist, such as a hepatologist .
Many people do not have any troublesome symptoms, but if you do feel unwell, it can help to:
- get plenty of rest
- take over-the-counter painkillers, such as paracetamol or ibuprofen, for tummy pain
- maintain a cool, well-ventilated environment, wear loose clothing, and avoid hot baths or showers if itching is a problem
- take medication, such as metoclopramide, to stop you feeling sick, and chlorphenamine to reduce itching your doctor can give you a prescription for these if necessary
Most people recover completely in a couple of months, but you’ll be advised to have regular blood tests to check that you’re free of the virus and have not developed chronic hepatitis B.
Also Check: If My Husband Has Hepatitis C Will I Get It
Living With Hepatitis B
If you have hepatitis, you should:
- avoid having unprotected sex, including anal and oral sex, unless you’re sure your partner has been vaccinated against hepatitis B
- avoid sharing needles used to inject drugs with other people
- take precautions to avoid the spread of infection, such as not sharing toothbrushes or razors with other people
- eat a generally healthy, balanced diet there’s no special diet for people with hepatitis B
- avoid drinking alcohol this can increase your risk of developing serious liver problems
- speak to your doctor if you’re thinking of having a baby
People with hepatitis B can usually have a healthy pregnancy, but it’s a good idea to discuss your plans with a doctor first as you may need extra care and your medications may need to be changed.
There’s a risk of pregnant women with hepatitis B passing the infection on to their child around the time of the birth, but this risk can be reduced by ensuring the baby is vaccinated shortly after they’re born.
Page last reviewed: 30 January 2019 Next review due: 30 January 2022
European Commission And Thervacb Join Forces
The role of viral hepatitis as a public health threat has long been underestimated. Only very recently, the United Nations in their 2030 Agenda for Sustainable Development called for international action to combat viral hepatitis and reduce the disease burden. The major killer is the hepatitis B virus causing liver cirrhosis and liver cancer. Worldwide 880,000 humans die each year from the consequences of an HBV infection.
A prophylactic vaccine is available to prevent HBV infection, but more than 3% of the worlds population are chronically infected and do not profit from that vaccine anymore. For those suffering from chronic hepatitis B, until today no curative treatment option exists.
The European Commission therefore selected the project TherVacB led by Helmholtz Zentrum München for a five-year funding within the Horizon 2020 program. A consortium of leading virologists, immunologists and physicians specialized in treating viral hepatitis, will use a newly designed therapeutic vaccine, TherVacB, as an immunotherapy to cure HBV. TherVacB will be evaluated in a three-year clinical trial starting in 2022 conducted in Europe and in Africa. Integration of a partner site in Tanzania shall help building local capacities for diagnosing and treating hepatitis B and support an important goal of the consortium to raise awareness for hepatitis B.
Don’t Miss: Can You Get Hepatitis C From Your Own Blood
For Media And Investors Only
Issued: London, UK
- Phase 2a data to be presented at The Digital International Liver Congress suggests potential of investigational drug to suppress hepatitis B virus after four weeks of treatment.
- Using pioneering antisense technology GSK836 delivered anti-viral activity, marking a potential step forward toward the goal of assessing a functional cure for people with chronic hepatitis B.
- GSK836 is on track to start a phase 2b programme by the end of 2020.
GSK today announced that GSK836 , an investigational antisense oligonucleotide, showed marked reductions in hepatitis B surface antigen and hepatitis B virus DNA compared with placebo after four weeks treatment in people with chronic hepatitis B on stable nucleoside or nucleotide analogue therapy and in patients who were NA-naïve.
These data from the 31 patients participating in the phase 2a study will be virtually presented at The Digital International Liver Congress 2020.
Chronic hepatitis B is a major global health problem caused by the hepatitis B virus. It is a long-lasting infection that occurs when the bodys immune system is unable to fight off the virus enabling it to persist in the blood and liver. Current treatment options, which include nucleoside/nucleotide analogues, can suppress but not clear the virus, so need to be taken for life.
For the selected 300mg dose of GSK836, reductions in HBsAg were observed in NA-treated and NA-naïve patients :
Whats New In Hepatitis B Cure 202:
Are there cases of hepatitis B cured? In fact, yes, with the new treatment for hepatitis B 2021-2022, a large number of hepatitis B cases have been cured, and the treatment is known as KA HEPA, which is manufactured by the Turkish company Kashgarli Sultan under the supervision of Dr. Marbouba Kashgarli. Sultan, which emphasized the ability of treatment to eliminate the disease completely.
Dr. Marbouba Kasherli, a physician specializing in ancient Uyghur medicine, has discovered many important natural remedies for many incurable diseases, the most important of which are the treatment of AIDS , the treatment of cancer , the treatment of blood pressure , rheumatism , Alzheimers treatment, and treatment of hepatitis B and C virus .
KA HEPA can also be obtained by contacting the company by clicking on the link below.
KA HEPA Features :
KA HEPA was manufactured by Kagarli Sultan Herbal Medicine Company according to the ancient Uyghur medicine. The treatment has proven to be a strong efficacy in getting rid of hepatitis C virus. According to a statement from Dr. Margoba Kashgarli Sultan, the treatment helped cure many cases of hepatitis C virus.
KA HEPA consists of a group of natural herbs that help reduce and eliminate the spread of the virus. This treatment is characterized by the following:
KA HEPA can also be obtained by contacting the company by clicking on the link below.
Don’t Miss: Hepatitis C Antigens And Antibodies
Persons New To Canada
Health care providers who see persons newly arrived in Canada should review the immunization status and update immunization for these individuals, as necessary. In many countries outside of Canada, HB vaccine is in limited use.
All persons from a country that is endemic for HB should be assessed and vaccinated against HB if not immune and not infected. Individuals born in developing countries are more likely to be carriers of HB, necessitating vaccination of their sexual and household contacts based on review of their serologic test results. HB vaccine is recommended for all household contacts whose families have immigrated to Canada from areas in which there is a high prevalence of HB and who may be exposed to HB carriers through their extended families or when visiting their country of origin.
Children adopted from countries in which there is a high prevalence of HB infection should be screened for HBsAg and, if positive, household or close contacts in the adopting family should be immunized before adoption or as soon as possible thereafter. Adults going to pick-up children from these countries should be vaccinated before departure. Refer to Immunization of Persons New to Canada in Part 3 for additional information.
Medical Treatment For Hepatitis A B & C
Treatment for hepatitis A, B, or C is based on which type of hepatitis is present in the bloodstream and the severity of the resulting liver damage. Depending on the results of diagnostic tests, our specialists at NYU Langone may recommend antiviral medication to stop the virus from replicating and protect your liver from further damage.
You May Like: How Hepatitis B And C Are Transmitted
New Combination Therapy Offers Chance Of Healing Hepatitis B
- German Center for Infection Research
- Around 260 million people, more than three percent of the global population, are chronically infected with the hepatitis B virus in the long term, this often leads to complications such as liver cirrhosis and liver cancer. A cure is not yet possible with the available medication. Scientists have now investigated a new combination therapy that has proven highly effective in their infection model.
The new therapeutic approach is based on shutting down the viral hepatitis B genome located in the nucleus of infected liver cells. Upon infection of the liver cell, the viral genome is transformed inside the nucleus into a closed circular DNA molecule. This deoxyribonucleic acid is a stable molecule known as covalently closed circular DNA and serves as the template for the production of new viruses. The cccDNA represents the central reservoir of the hepatitis B viruses and enables their persistence in the liver. The virologist Prof. Dr. Maura Dandri and her team at the UKE managed to prevent the HBV-cccDNA from producing further viruses in the animal model.
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted For Presentation At Aaslds The Liver Meeting 2021
SAN FRANCISCO, Oct. 15, 2021 — Vir Biotechnology Inc. today announced that three abstracts highlighting data from its hepatitis B clinical program and one health outcomes research abstract have been accepted for oral and poster presentation at the American Association for the Study of Liver Diseases The Liver Meeting®, taking place virtually from November 12-15, 2021.
Among the accepted abstracts is an oral presentation of new data from a Phase 2 study evaluating VIR-2218, an investigational small interfering ribonucleic acid that mediates RNA interference , alone and in combination with pegylated interferon alfa-2a , an approved immunomodulator for the treatment of chronic hepatitis B virus , for the potential functional cure of chronic HBV infection.
Additionally, two poster presentations will highlight pre-clinical and clinical data for VIR-3434, an investigational HBV-neutralizing monoclonal antibody designed to inhibit HBV entry into cells, reduce the number of virion and subvirion particles in the blood, and potentially function as a therapeutic T cell vaccine. A third poster presentation will focus on the impact of chronic HBV and its treatments on patients lives, as well as the perceived value of a functional cure.
Presentation details are as follows:
New Immunotherapy ‘highly Effective’ Against Hepatitis B
- University College London
- Scientists have identified a new immunotherapy to combat the hepatitis B virus , the most common cause of liver cancer in the world.
Scientists at UCL have identified a new immunotherapy to combat the hepatitis B virus , the most common cause of liver cancer in the world.
Each year, globally, chronic HBV causes an estimated 880,000 deaths from liver cirrhosis and hepatocellular carcinoma/liver cancer .
The pioneering study used immune cells isolated directly from patient liver and tumour tissue, to show that targeting acyl-CoA:cholesterol acyltransferase , an enzyme that helps to manage cholesterol levels in cells*, was highly effective at boosting immune responses.
Published in Nature Communications, the findings show that blocking the activity of ACAT with ACAT inhibitors boosts the specific immune cells that can fight both the virus and associated cancerous tumours, demonstrating its effectiveness as an immunotherapy. Inhibiting ACAT was also found to impede HBV’s own replication, thereby also acting as a direct antiviral. ACAT inhibitors such as avasimibe, taken orally, have previously been shown to be well-tolerated as cholesterol-lowering drugs in humans.
Explaining the study, lead author Professor Mala Maini , said: “Chronic hepatitis B virus infection is a major global health problem and the most common cause of liver cancer in the world.
Grant funding came from the Wellcome Trust and Cancer Research UK.
Hbsag Clearance After Na Treatment
There are few large or conclusive studies on the clearance of HBsAg after NA treatment, and some of these studies are single-centre retrospective studies. Kim et al. reported a clearance rate of 1% or less in 110 CHB patients who were treated with ETV/LAM for approximately 1 year. A retrospective study by Yip et al. reported an HBsAg clearance rate of 2.1% after an average follow-up of 4.8 years in 20,263 CHB patients treated with ETV/TDF for longer than 6 months. Wong et al. retrospectively evaluated 1072 CHB patients on antiviral therapy for approximately 6 years and found an HBsAg clearance rate of 4.58%. This study found no significant difference in the clearance rate between HBeAg-positive and HBeAg-negative patients, but the rate in patients with cirrhosis was significantly lower than patients without cirrhosis . These results suggested that the clearance rate of non-cirrhosis patients was higher after NA treatment, which is not consistent with the results of patients who experienced spontaneous clearance. Compared to patients with normal baseline ALT, patients with higher ALT levels had significantly higher rates of achieving HBsAg clearance. In general, the clearance rate may increase with the extension of treatment in CHB patients, but the overall rate with currently available NA treatment is low. The HBsAg clearance rates were 1.45.1% after an average follow-up of 27 years after NA treatment .
Don’t Miss: How Do You Get Hepatitis A From Food
Modulation Of The Adaptive Immune System
6.2.1. Therapeutic Vaccination
Previous attempts at different times during the past two decades, using existing prophylactic vaccines with varying vaccination strategies, have failed to restore HBV-specific immunity in chronically infected patients. When used in animal models, they provided promising results, which were not replicated in human subjects . Such vaccines which employed an adjuvant, although capable of stimulating a robust B cell response, failed to induce the cytotoxic arm of the immune response which was necessary to achieve a therapeutic outcome. In an attempt to overcome this disadvantage, DNA vaccine strategies were introduced employing coding sequences of HBsAg but, once again, yielded poor results in patients virally suppressed by analogue treatment. Notably, they failed to lead to either HBeAg or HBsAg seroconversion . Of similar faith, was the use of DNA prime followed by poxvirus boost, the latter containing the preS/S encoding region. Although promising results were obtained once again in the chimpanzee animal model , in a phase IIa trial this approach did not induce sustained T cell responses or achieve a sizeable reduction in viral load in chronic HBV carriers .
6.2.2. More Recent Approaches
6.2.3. Vector-Based Vaccines
6.2.4. Adoptive Transfer of Genetically Engineered T Cells
Hepatitis B: A New Weapon Against An Old Enemy
volume 27, pages 16721673
New strategies based on nucleic acid technologies are being exploited to treat chronic hepatitis Ba pilot clinical study of antisense oligonucleotide treatment shows the potential promise of this approach.
Chronic infection with hepatitis B virus afflicts more than 250 million people worldwide. Effective vaccines and treatments that potently suppress viral levels and reduce liver inflammation have been available for over 20 years, but infection with HBV continues to exact a heavy public-health toll. The goal of a cure for chronic infection with HBV remains elusive. At present, nucleoside analogs and interferon- are the only approved therapies, and they rarely cure the infection. Even in patients with serological recovery and HBV DNA, with normal liver tests), HBV can persist in small quantities and can be reactivated when host antiviral immunity is perturbed. However, most people with serological recovery have few or no clinical consequences thus, the current development of therapeutics against HBV is focused on achieving this state the so-called functional cure through various pharmacological approaches. In this issue of Nature Medicine, Yuen et al. describe the application of antisense oligonucleotide technology to suppress HBV replication in patients with chronic infection with HBV.
This is a preview of subscription content
Read Also: Can You Catch Hepatitis C From Kissing